Life Sciences Xi L.P. Frazier Acquires 588,235 Shares of Attovia Therapeutics (NASDAQ:ATTO) Stock

Attovia Therapeutics, Inc. (NASDAQ:ATTO) major shareholder Life Sciences Xi L.P. Frazier bought 588,235 shares of Attovia Therapeutics stock in a transaction that occurred on Thursday, August 6th. The shares were acquired at an average cost of $17.00 per share, for a total transaction of $9,999,995.00. Following the completion of the transaction, the insider directly owned 6,154,213 shares in the company, valued at $104,621,621. This represents a 10.57% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Attovia Therapeutics Stock Down 6.9%

Shares of Attovia Therapeutics stock traded down $1.52 during midday trading on Thursday, hitting $20.38. The company had a trading volume of 413,197 shares. Attovia Therapeutics, Inc. has a 12-month low of $19.63 and a 12-month high of $22.79.

About Attovia Therapeutics

Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company’s research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs.

Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways.